Table 3. Clinical Trials of AZD1775 and Their Status, Purpose, and Conditionsa.
| S. no. | NCT number | status | therapy | drugs | phase | conditions | purpose |
|---|---|---|---|---|---|---|---|
| 1 | NCT02508246 | C | CT | AZD1775, CDDP, Docetaxel | 1 | HNSCC | side effects and the best dose of AZD1775 in combination with CDDP, Docetaxel |
| 2 | NCT02666950 | C | MT, CT | AZD1775, AraC | 2 | advanced acute myeloid leukemia and myelodysplastic syndrome | competency of AZD1775 with and without Cytarabine |
| 3 | NCT02196168 | T | CT | CDDP, AZD1775 | 2 | recurrent or metastatic squamous cell cancer of the head and neck | competency of AZD1775 with and without CDDP |
| 4 | NCT02194829 | A | CT | AZD1775, Gemcitabine Hydrochloride, Nab-paclitaxel | 1 | metastatic adenocarcinoma of the pancreas | side effects and best dose of AZD1775 in combination with Nab-paclitaxel, Gemcitabine Hydrochloride |
| 5 | NCT02381548 | T | CT | AZD1775, Belinostat | 1 | relapsed and refractory myeloid malignancies and acute myeloid leukemia | side effects and best dose of AZD1775 and Belinostat |
| 6 | NCT01164995 | A | CT | AZD1775, Carboplatin | 2 | epithelial ovarian cancer | proof of concept (POC) study to prove WEE1 inhibition as an effective treatment in TP53 mutants |
| 7 | NCT02906059 | C | CT | AZD1775, Irinotecan | 1 | RAS or BRAF mutated metastatic colorectal cancer | safety and effectiveness in RAS or BRAF mutants |
| 8 | NCT03028766 | C | CT | AZD1775, CDDP, radiotherapy | 1 | head and neck cancer | best dose of AZD1775 in combination with CDDP |
| 9 | NCT02101775 | A | CT | AZD1775, Gemcitabine Hydrochloride | 2 | recurrent, platinum resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers | comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 |
| 10 | NCT02037230 | C | CT | AZD1775, Gemcitabine, radiotherapy | 1, 2 | adenocarcinoma of the pancreas | maximum tolerated dose (MTD) of AZD1775 |
| 11 | NCT04460937 | S | CT | AZD1775, radiotherapy | 1 | esophageal and gastresophageal junction cancer | maximally tolerated dose (MTD) of AZD1775 |
| 12 | NCT01748825 | C | MT | AZD1775 | 1 | advanced refractory solid tumors | safety, tolerability, and PK |
| 13 | NCT03253679 | S | MT | AZD1775 | 2 | advanced malignant solid neoplasm and refractory malignant solid neoplasm | objective response rate (ORR) to AZD1775 |
| 14 | NCT03668340 | R | MT | AZD1775 | 2 | uterine cancer | safety and effectiveness of AZD1775 |
| 15 | NCT03315091 | C | MT | AZD1775 | 1 | solid tumors | effect of food on the pharmacokinetics (PK) |
| 16 | NCT02207010 | C | MT | AZD1775 | 0 | glioblastoma multiforme (GBM) | CNS penetration |
| 17 | NCT02688907 | T | MT | AZD1775 | 2 | small cell lung cancer | competency of AZD1775 in MYC family amplification or CDKN2A mutation in TP53 mutants |
| 18 | NCT02593019 | C | MT | AZD1775 | 2 | small cell lung cancer | competency of AZD1775 in TP53 mutants |
| 19 | NCT02585973 | C | CT | AZD1775, CDDP, intensity modulated radiotherapy | 1b | carcinoma, squamous cell of head and neck | dose-escalation trial |
| 20 | NCT02791919 | W | CT | AZD1775, AraC, Fludarabine Phosphate | 1 | relapsed or refractory acute myeloid leukemia | dose-escalation trial, toxicity, PK |
| 21 | NCT03385655 | R | CT | AZD1775, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab, and Tremelimumab, Carboplatin | 2 | prostate cancer | DNA abnormalities or biomarkers |
| 22 | NCT03313557 | C | MT | AZD1775 | 1 | solid tumors | safety and tolerability |
| 23 | NCT03333824 | C | CT | AZD1775, caffeine (CYP1A2), omeprazole (CYP2C19), midazolam (CYP3A), granisetron | 1 | advanced solid tumors | effect of AZD1775 on PK of other drugs |
| 24 | NCT03345784 | A | CT | AZD1775, CDDP, external beam radiation therapy | 1 | cervical, upper vaginal, and uterine cancers | recommended phase-II dose (RP2D) and safety profile of AZD1775 |
| 25 | NCT02610075 | C | MT | AZD1775 | 1 | solid tumors | determine maximum tolerant dose (MTD) |
| 26 | NCT02482311 | C | MT | AZD1775 | 1 | solid tumors | safety, tolerability, and PK |
| 27 | NCT02511795 | C | CT | AZD1775, Olaparib | 1 | refractory solid tumors and SCLC | dose-escalation trial |
| 28 | NCT02087176 | T | CT | AZD1775, antimitotic agent, Pegfilgrastim | 2 | previously treated SCLC | comparative study of AZD1775+antimitotic agent with placebo |
| 29 | NCT02341456 | C | MT, CT | AZD1775, Paclitaxel, Carboplatin | 1 | advanced solid tumors | multicenter study in adult asian patients |
| 30 | NCT02513563 | W | CT | AZD1775, Paclitaxel, Carboplatin | 1 | lung cancer | effects of AZD1775 |
| 31 | NCT02087241 | T | CT | AZD1775, Pemetrexed, Carboplatin | 2 | advanced NSCLC | comparative study of chemotherapy with and without AZD1775 |
| 32 | NCT03718143 | T | MT, CT | AZD1775,AraC | 2 | myelofibroses, acute myeloid leukemia, myelodysplastic syndromes | effects of AZD1775 as a single agent and in combination with AraC |
| 33 | NCT03012477 | C | CT | AZD1775, CDDP | 2 | breast cancer | effects of AZD1775 |
| 34 | NCT01047007 | T | MT, CT | AZD1775, CDDP, 5-FU | 1 | solid tumors | safety and MTD of AZD1775 |
| 35 | NCT02448329 | C | CT | AZD1775, Paclitaxel | 2 | advanced gastric adenocarcinoma | effects of AZD1775 |
| 36 | NCT04462952 | C | MT | AZD1775 | 1 | advanced solid tumors | safety, tolerability, pharmacokinetics (PK), and antitumor activity |
| 37 | NCT04439227 | A | MT | AZD1775 | 2 | lymphoma, neoplasm, myeloma | effect of AZD1775 on BRCA mutants |
| 38 | NCT01076400 | T | CT | AZD1775, Topotecan, CDDP | 1, 2 | cervical cancer | safety and MTD of AZD1775 |
| 39 | NCT01357161 | C | CT | AZD1775, Paclitaxel, CDDP | 2 | ovarian cancer | safety and efficacy of AZD1775 |
| 40 | NCT00648648 | C | CT | AZD1775, CDDP, Carboplatin, Gemcitabine | 1 | solid tumors | dose-escalation trial |
| 41 | NCT03284385 | A | MT | AZD1775 | 2 | SETD2-deficient solid tumors | effect of AZD1775 on SETD2 mutants |
| 42 | NCT04197713 | S | CT | AZD1775, Olaparib | 1 | solid tumors | side effects and best dose of AZD1775 |
| 43 | NCT02095132 | A | CT | AZD1775,Irinotecan | 1, 2 | solid tumors | side effects and best dose of AZD1775 |
| 44 | NCT01922076 | C | CT | AZD1775, radiotherapy | 1 | diffuse intrinsic pontine gliomas | side effects and best dose of AZD1775 |
| 45 | NCT01849146 | A | CT | AZD1775, radiotherapy, Temozolomide | 1 | glioblastoma | side effects and best dose of AZD1775 |
| 46 | NCT03579316 | R | MT, CT | AZD1775,Olaparib, Ceralasertib | 2 | recurrent fallopian tube, ovarian, primary peritoneal carcinomas | comparative study of AZD1775 with and without PARP inhibitors |
| 47 | NCT05008913 | T | MT | AZD1775 | 1 | advanced solid tumors | ADME study |
| 48 | NCT04949425 | T | MT | AZD1775 | 1 | advanced solid tumors | safety and tolerability study |
| 49 | NCT04590248 | A | MT | AZD1775 | 2 | uterine serous carcinoma | safety and efficacy of AZD1775 |
| 50 | NCT05212025 | W | CT | AZD1775, Gemcitabine | 2 | pancreatic cancer | safety and efficacy of the combination |
| 51 | NCT02546661 | A | MT,CT | AZD1775,AZD4547,MEDI4736, Olaparib, Vistusertib, AZD9150, Selumetinib | 1 | muscle invasive bladder cancer | safety, tolerability, pharmacokinetics (PK), and antitumor activity |
| 52 | NCT02937818 | A | CT | AZD1775, CBDP | 2 | platinum refractory extensive-stage SCLC | efficacy, safety, and tolerability |
| 53 | NCT02659241 | A | MT | AZD1775 | 1 | advanced fallopian tube, ovarian, primary peritoneal carcinomas | effects of AZD1775 |
| 54 | NCT02272790 | A | CT | AZD1775,CBDP, Paclitaxel, PLD, Gemcitabine | 2 | ovarian, fallopian tube, peritoneal cancer | efficacy and safety |
| 55 | NCT03330847 | A | CT | AZD1775,Olaparib, Ceralasertib | 2 | breast cancer | safety and efficacy of Olaparib in combination with AZD1775 and Ceralasertib |
| 56 | NCT01827384 | C | CT | AZD1775, Carboplatin, Everolimus, Temozolomide, Trametinib Veliparib | 2 | advanced malignant solid neoplasm | molecular profiling-based assignment of cancer therapy |
| 57 | NCT02465060 | A | CT | AZD1775, target-oriented inhibitors | 2 | solid tumors, lymphomas | genetic testing for targeted therapy |
a
C, completed; R, recruiting; A, active; S, suspended; T, terminated; W, withdrawn; CT, combination therapy; and MT, monotherapy.